Triage III study supports use of suPARnostic® in Emergency Departments

Mon Sep 10 2018

Data from the TRIAGE III study were presented at the 12th European Congress of Emergency Medicine in Glasgow, and shows that use of suPARnostic® Quick Triage shortened patients’ stay at Emergency Departments by 6.5 hours and allowed a significantly higher proportion of patients to be discharged within 24 hours.

The study measured the effect of  suPARnostic® Quick Triage compared to conventional triage/risk stratification systems used in emergency departments. The TRIAGE III cluster-randomised controlled study included 16,801 patients of whom 7,905 patients had their level of suPAR protein in the bloodstream determined quickly and the result conveyed to doctors and nurses in the emergency department.

The study results demonstrated superiority of suPAR as a prognostic biomarker compared to other investigated biomarkers (e.g. age, CRP, albumin), including a combined model of commonly used routine blood tests, in predicting short-term mortality. After a median follow-up of 362 days, death occurred in 13.9% in the suPAR group and in 14.3% of the patients in the control group (not significant).

Patients, whose level of suPAR had been established by suPARnostic® Quick Triage,  experienced a significantly shorter stay at the emergency departments  (mean: 6,5 hours shorter stay) and a significantly higher proportion of suPAR-patients were discharged within 24 hours compared to the control group (both statistically significant at p<0.05).

Data from the TRIAGE III study were presented by investigator Martin Schultz, MD. Please find the abstract text here;

Dr Schultz concluded that a low suPAR level may be used to identify patients with a good prognosis, and who are at very low risk of short-term mortality.
This is of particular value to emergency departments required to assess larger number of patients in a short time.
Improving patient flow by early discharge of low-risk patients, where admission might not be necessary, will potentially benefit both patients in need of hospital treatment and low-risk patients that can be discharged without being exposed to the risks of hospitalization.

All in all, these data show that measuring suPAR in Emergency Departments help physicians take faster decisions about discharge, without affecting the mortality, thus saving healthcare systems valuable time and resources.

The TRIAGE III trial was a cluster-randomized interventional trial conducted at emergency departments at Herlev Hospital and Bispebjerg Hospital in the Capital Region of Denmark. The inclusion period was from January through June of 2016 and consisted of twelve cluster-periods of 3-weeks alternating between intervention and control and a subsequent follow-up of ten months.The study has been registered in, NCT02643459


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates